The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia
Open Access
- 15 August 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (4), 1215-1219
- https://doi.org/10.1182/blood.v100.4.1215.h81602001215_1215_1219
Abstract
Tumor necrosis factor-α (TNF-α), a cytokine possessing pleiotropic biological activities, is produced by leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL) and acts as an autocrine and paracrine growth factor in this disease. In this study, TNF-α levels were determined in 150 patients with CLL and correlated with disease characteristics, prognostic factors, and survival. The mean TNF-α plasma concentration in the patients with CLL was significantly higher than in the healthy control population (16.4 versus 8.7 pg/mL; P < .0001). Patients having an elevated TNF-α level had more advanced Rai and Binet stage disease, higher serum β2-microglobulin (β2M) levels, a greater percentage of cells expressing CD38, and lower hemoglobin and platelet levels. Patients having chromosomal abnormalities such as 11q deletion, trisomy 12, and chromosome 17 aberrations had a higher mean TNF-α level (27.5 pg/mL) than patients having a diploid karyotype or other miscellaneous cytogenetic abnormalities (14.2 pg/mL;P < .001). The TNF-α level was a predictor of survival when the Cox proportional hazards model was used with TNF-α entered as a continuous variable (P = .0001). Also, patients having a TNF-α level above the mean value of 14 pg/mL had significantly shorter survival duration (P = .00001). The TNF-α level remained predictive of survival in Cox multivariate analysis independent of Rai staging and β2M, hemoglobin, prior therapy, white cell count, and platelet level (P = .005). We conclude that the TNF-α level serves as a prognostic factor in patients with CLL and that inhibition of TNF-α in these patients could have therapeutic importance.Keywords
This publication has 23 references indexed in Scilit:
- Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-α double-deficient miceInternational Immunology, 1996
- TNF Receptors in Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1994
- Haematologic effects of TNFResearch in Immunology, 1993
- Heterogeneous proliferative effect of tumor necrosis factor-α and lymphotoxin on mitogen-activated B cells from B-chronic lymphocytic leukemiaAmerican Journal of Hematology, 1993
- Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesisThe International Journal of Cell Cloning, 1993
- Differential secretion of tumor necrosis factor-α and granulocyte/macrophage colony-stimulating factors but not interferon-γ from CD4 compared to CD8 human T cell clonesEuropean Journal of Immunology, 1989
- TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIESThe Lancet, 1988
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemiaNature, 1987
- Secretory products of macrophages.JCI Insight, 1987
- Tumour necrosis factor is a compact trimerFEBS Letters, 1987